NeoStem, Inc. (NYSE Amex: NBS) Announces Participation in Multiple January Conferences

NeoStem, Inc. (NYSE Amex: NBS) Announces Participation in Multiple January Conferences

NeoStem, Inc. (NYSE Amex: NBS) is an international biopharmaceutical company focused on cell-based therapeutic development. Its January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") is central to the Company's strategic mission of capturing the paradigm shift to cell therapy. The acquisition of PCT gives NeoStem not only access to a world class contract manufacturing cell therapy company but provides a platform and expertise around the evaluation, development and regulatory requirements to develop autologous, allogeneic, immunomodulatory and vaccine-based therapeutics.

Today, the company announced that it will be presenting with PCT at four upcoming January conferences: Biotech Showcase 2012, Noble Financial Capital Markets Equity Conference, ECI's Inaugural Scale-Up and Manufacturing of Cell-Based Therapies, and Phacilitate's Cell & Gene Therapy Forum 2012.

NeoStem Chairman and CEO Dr. Robin L. Smith commented:

"This list of January events demonstrates our widespread involvement in various industry forums and investor conferences that give us the opportunity to highlight our cell therapy industry expertise designed to put us at the forefront in transforming chronic disease through the application of cell based medicine while strategically providing revenues from our contract cGMP manufacturing of a variety of product candidates under development."

Biotech Showcase 2012 - January 10, 2012, San Francisco, California - Park 55 Wyndham.

8:00 - 9:30 AM - Dr. Robin L. Smith, Chairman and CEO of NeoStem, will present as part of a panel discussion entitled "Regenerative Medicine State of the Industry Briefing."

10:30 AM - Dr. Robin L. Smith, Chairman and CEO of NeoStem, will present on NeoStem in Track C.

 9:30 - 11:00 AM - Dr. Andrew L. Pecora, Chief Medical Officer of NeoStem, will present on Amorcyte, a NeoStem company developing novel treatments for cardiovascular disease, as part of a panel discussion entitled "Cardiovascular, AMI and PAD-Part 1".

ECI's Inaugural Scale-Up and Manufacturing of Cell-Based Therapies - January 11-13, 2012, San Diego, California - Catamaran Resort Hotel

10:40 AM on Thursday, January 12 - Dr. Robert A. Preti, President of PCT, will chair a session titled "Process Development Challenges for Autologous Cell Therapies".

11:55 AM on Friday, January 13 - Dr. Robert A. Preti, President of PCT, will speak in Session 6, "Business Models", about "Considerations in scale up of autologous and allogeneic cell therapies: implications to cost of goods".

Noble Financial Capital Markets Equity Conference - January 17-18, 2012, Hollywood, Florida - Hard Rock Hotel

12:00 PM on Wednesday, January 18 - Jason Kolbert, NeoStem's Vice President of Strategic Business Development, will present on NeoStem.

Phacilitate Cell & Gene Therapy Forum 2012 - January 30 - February 1, 2012, Washington DC - The Grand Hyatt

2:10 PM on Monday, January 30 - Dr. Sanjin Zvonic, Director, Technology & Business Development, PCT, will present during a session titled "Beyond scale-up: Managing the delivery and bedside integrity of cryopreserved cell therapy products".

3:25 PM on Tuesday, January 31 - Dr. Robert A. Preti, President of PCT, will present during a session titled "Cell therapy and tissue engineered product translational R&D strategy: What advice can companies that have successfully advanced into clinical trials impart?"

Read the full release on PR Newswire.